A detailed history of Bourne Lent Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bourne Lent Asset Management Inc holds 157,192 shares of BMY stock, worth $8.84 Million. This represents 3.09% of its overall portfolio holdings.

Number of Shares
157,192
Previous 158,687 0.94%
Holding current value
$8.84 Million
Previous $6.59 Million 23.43%
% of portfolio
3.09%
Previous 2.53%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$39.66 - $51.75 $59,291 - $77,366
-1,495 Reduced 0.94%
157,192 $8.13 Million
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $155,566 - $204,806
-3,865 Reduced 2.38%
158,687 $6.59 Million
Q1 2024

Apr 12, 2024

SELL
$47.98 - $54.4 $273,725 - $310,352
-5,705 Reduced 3.39%
162,552 $8.82 Million
Q4 2023

Jan 19, 2024

SELL
$48.48 - $57.85 $811,264 - $968,061
-16,734 Reduced 9.05%
168,257 $8.63 Million
Q3 2023

Oct 19, 2023

SELL
$57.89 - $64.73 $1.24 Million - $1.38 Million
-21,362 Reduced 10.35%
184,991 $10.7 Million
Q2 2023

Jul 17, 2023

SELL
$63.71 - $70.74 $299,437 - $332,478
-4,700 Reduced 2.23%
206,353 $13.2 Million
Q1 2023

Apr 24, 2023

SELL
$65.71 - $74.53 $39,425 - $44,718
-600 Reduced 0.28%
211,053 $14.6 Million
Q4 2022

Jan 23, 2023

SELL
$68.48 - $81.09 $5.61 Million - $6.64 Million
-81,875 Reduced 27.89%
211,653 $0
Q3 2022

Oct 31, 2022

SELL
$0.13 - $76.84 $223 - $132,164
-1,720 Reduced 0.58%
293,528 $20.9 Million
Q2 2022

Jul 27, 2022

SELL
$72.62 - $79.98 $130,716 - $143,964
-1,800 Reduced 0.61%
295,248 $22.7 Million
Q1 2022

Apr 26, 2022

SELL
$61.48 - $73.72 $1.44 Million - $1.73 Million
-23,450 Reduced 7.32%
297,048 $21.7 Million
Q4 2021

Jan 20, 2022

SELL
$53.63 - $62.52 $2.39 Million - $2.78 Million
-44,474 Reduced 12.19%
320,498 $20 Million
Q2 2021

Jul 28, 2021

SELL
$61.91 - $67.42 $1.35 Million - $1.47 Million
-21,744 Reduced 5.62%
364,972 $24.4 Million
Q1 2021

Apr 23, 2021

SELL
$59.34 - $66.74 $348,088 - $391,496
-5,866 Reduced 1.49%
386,716 $24.4 Million
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $1.08 Million - $1.22 Million
-18,643 Reduced 4.53%
392,582 $24.4 Million
Q3 2020

Oct 19, 2020

SELL
$57.43 - $63.64 $393,969 - $436,570
-6,860 Reduced 1.64%
411,225 $24.8 Million
Q2 2020

Jul 20, 2020

SELL
$54.82 - $64.09 $95,935 - $112,157
-1,750 Reduced 0.42%
418,085 $24.6 Million
Q1 2020

Apr 17, 2020

SELL
$46.4 - $67.43 $134,560 - $195,547
-2,900 Reduced 0.69%
419,835 $23.4 Million
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $20.4 Million - $26.7 Million
415,315 Added 5597.24%
422,735 $27.1 Million
Q3 2019

Oct 24, 2019

SELL
$42.77 - $50.71 $17,108 - $20,284
-400 Reduced 5.12%
7,420 $376,000
Q2 2019

Jul 29, 2019

SELL
$44.62 - $49.34 $8,924 - $9,868
-200 Reduced 2.49%
7,820 $355,000
Q4 2018

Jan 28, 2019

BUY
$48.76 - $63.23 $112,148 - $145,429
2,300 Added 40.21%
8,020 $417,000
Q2 2018

Jul 25, 2018

SELL
$50.53 - $62.98 $85,901 - $107,066
-1,700 Reduced 22.91%
5,720 $317,000
Q4 2017

Feb 06, 2018

SELL
$59.94 - $65.35 $5,994 - $6,534
-100 Reduced 1.33%
7,420 $455,000
Q3 2017

Oct 16, 2017

BUY
$55.23 - $63.74 $415,329 - $479,324
7,520
7,520 $479,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bourne Lent Asset Management Inc Portfolio

Follow Bourne Lent Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bourne Lent Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bourne Lent Asset Management Inc with notifications on news.